Satoreotide Tetraxetan features a somatostatin-analog peptide linked to a tetraxetan chelator suitable for radiometal coordination studies. Cyclic backbone constraints promote defined receptor-binding conformations. Researchers investigate its metal-loading behavior, stability, and stereochemical preferences. Use spans receptor-ligand modeling, coordination chemistry, and radiometal-chelate optimization in preclinical systems.
CAT No: R2539
CAS No:1039726-31-2
Synonyms/Alias:DOTA satoreotide;Satoreotide DOTA;Satoreotide tetraxetan;EC1O2FB9FV;DOTA-JR-11;1039726-31-2;UNII-EC1O2FB9FV;DOTA-JR11;satoreotida tetraxetan;SATOREOTIDE TETRAXETAN [INN];D-TYROSINAMIDE, 4-CHLORO-N-(2-(4,7,10-TRIS(CARBOXYMETHYL)-1,4,7,10-TETRAAZACYCLODODEC-1-YL)ACETYL)-L-PHENYLALANYL-D-CYSTEINYL-4-((((4S)-HEXAHYDRO-2,6-DIOXO-4-PYRIMIDINYL)CARBONYL)AMINO)-L-PHENYLALANYL-4-((AMINOCARBONYL)AMINO)-D-PHENYLALANYL-L-LYSYL-L-THREONYL-L-CYSTEINYL-, CYCLIC (2->7)-DISULFIDE;satoreotidum tetraxetanum;CHEMBL4297531;EX-A5520;HY-P5128;DA-63000;CS-0775089;
3. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review
5. High fat diet and GLP-1 drugs induce pancreatic injury in mice
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.